To highlight the challenges and necessary improvements in laboratory response to measles outbreaks in the US, particularly in the context of declining vaccination rates.
Approach:
Vaccination Trends: Describes the decline in national vaccination coverage due to factors such as the COVID-19 pandemic and vaccine skepticism.
Clinical Risks: Details the acute and long-term complications associated with measles, including immune amnesia and SSPE.
Laboratory Challenges: Discusses the absence of FDA-cleared assays for measles and the reliance on laboratory-developed tests.
Testing Plans: Stresses the importance of having a testing plan and communication with public health laboratories.
Advances in Diagnostics: Highlights recent advances in PCR testing for earlier detection of measles.
Key Findings:
Vaccination coverage has declined, with some communities below 50% MMR vaccination.
Measles can lead to serious complications, including immune amnesia and SSPE.
No FDA-cleared assays for measles exist, relying on laboratory-developed tests.
PCR testing can detect measles earlier than IgM serology and distinguish between wild-type and vaccine strains.
Clear communication between clinical and public health laboratories is essential during outbreaks.
Interpretation:
The article underscores the urgent need for improved laboratory capabilities and preparedness in response to measles outbreaks.
Limitations:
No FDA-approved assays for measles testing.
Limited capacity for developing and validating tests in many clinical laboratories.
Conclusion:
Laboratories must enhance their testing protocols and communication strategies to effectively manage measles outbreaks.
